Difference between revisions of "LncARSR"

From LncRNAWiki
Jump to: navigation, search
(Created page with " ==Annotation== ===Name=== lncARSR ===Alias=== NA ===Disease=== Disease: renal cell cancer [http://www.ncbi.nlm.nih.gov/pubmed/27117758 (PMID:27117758)] Dysfunction type: e...")
 
Line 1: Line 1:
 +
''lncARSR'', a lncRNA regulator of Akt signaling associated with HCC and RCC
  
−
==Annotation==
+
==Annotated Information==
−
===Name===
+
===Approved Symbol===
−
lncARSR
+
''lncARSR''
  
−
===Alias===
+
===Approved Name===
−
NA
+
''lncARSR'': lncRNA regulator of Akt signaling associated with HCC and RCC
  
−
===Disease===
+
===Characteristics===
−
Disease: renal cell cancer [http://www.ncbi.nlm.nih.gov/pubmed/27117758 (PMID:27117758)]
+
''lncARSR'' (lncRNA Activated in RCC with Sunitinib Resistance) is located on chromosome 9 in humans and composed of four exons with a full length of 591 nt determined by RACE. <ref name="ref1" />
  
−
Dysfunction type: expression
+
===Function===
 +
''lncARSR'' acts as a ceRNA for miR-34 and miR-449 to promote AXL and c-MET expression <ref name="ref1" /> .
 +
''lncARSR'' promotes the self-renewal capacity, tumorigenicity and metastasis of renal T-ICs <ref name="ref2" />.
 +
''lncARSR'' plays a critical role in renal T-ICs propagation and may serve as a prognostic biomarker and potential therapeutic target <ref name="ref2" />.
 +
''lncARSR'' physically associates with PTEN mRNA, promotes PTEN mRNA degradation, decreases PTEN expression, and activates PI3K/Akt pathway <ref name="ref3" />.
 +
Long noncoding RNA ''lncARSR'' promotes hepatic lipogenesis via Akt/SREBP-1c pathway and contributes to the pathogenesis of nonalcoholic steatohepatitis <ref name="ref4" />.
 +
Upregulated ''lncARSR'' promotes hepatic cholesterol biosynthesis via modulating Akt/SREBP-2/HMGCR pathways <ref name="ref5" />
  
−
Description: LncARSR may serve as a predictor and a potential therapeutic target for sunitinib resistance.
+
===Regulation===
 +
Transfection of constitutively active FOXO1 (FOXO1-A3) or FOXO3a (FOXO3a-A3) significantly downregulated ''lncARSR'' levels in sunitinib-resistant cells <ref name="ref1" />
  
 +
===Diseases===
 +
*Hepatocellular Carcinoma <ref name="ref3" />
 +
*Renal cancer <ref name="ref1" />
  
−
===Function===
+
===Expression===
−
Function Mechanism: ceRNA [http://www.ncbi.nlm.nih.gov/pubmed/27117758 (PMID:27117758)]
+
''lncARSR'' is preferentially upregulated in renal T-ICs <ref name="ref2" /> .
 +
''lncARSR'' is upregulated in HCC, associated with large tumor size and advanced BCLC stage <ref name="ref3" />.
 +
Overexpression of ''lncARSR'' enhance while knockdown of ''lncARSR'' ameliorated hepatic lipid accumulation in vivo and in vitro <ref name="ref4" />.  
 +
 
 +
==Labs working on this lncRNA==
 +
*Department of Urology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China
 +
*Intensive Care Unit, The Affiliated Hospital of Weifang Medical University, Weifang, Shandong, 261031, China
 +
*Department of Medical Equipment, Weifang People's Hospital, Weifang, Shandong, 261000, China
  
−
Biological Process: pathogenic process
+
==References==
 +
<references>
 +
<ref name="ref1"> Qu L, Ding J, Chen C, Wu ZJ, Liu B, Gao Y et al. Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA[J]. Cancer Cell. 2016, 29(5):653-668.
 +
</ref>(1)
 +
<ref name="ref2"> Qu L, Wu ZJ, Li YM, Xu ZP, Liu B, Liu F et al. A feed-forward loop between lncARSR and YAP activity promotes expansion of renal tumour-initiating cells[J]. Nature communications. 2016
 +
</ref>(2)
 +
<ref name="ref3"> Li YL, Ye Y, Feng BM & Qi Y. Long Noncoding RNA lncARSR Promotes Doxorubicin Resistance in Hepatocellular Carcinoma via Modulating PTEN-PI3K/Akt Pathway[J]. J Cell Biochem. 2017, 118(12):4498-4507.
 +
</ref>(3)
 +
<ref name="ref4"> Zhang M, Chi X, Qu N & Wang C. Long noncoding RNA lncARSR promotes hepatic lipogenesis via Akt/SREBP-1c pathway and contributes to the pathogenesis of nonalcoholic steatohepatitis[J]. Biochem Biophys Res Commun. 2018, 499(1):66-70.
 +
</ref4>
 +
<ref name="ref5"> Huang J, Chen S, Cai D, Bian D & Wang F. Long noncoding RNA lncARSR promotes hepatic cholesterol biosynthesis via modulating Akt/SREBP-2/HMGCR pathway[J]. Life sciences. 2018
 +
</ref5> 
 +
</references>
  
−
Description: NA
+
===Sequence===
 +
NA

Revision as of 06:23, 7 December 2018

lncARSR, a lncRNA regulator of Akt signaling associated with HCC and RCC

Annotated Information

Approved Symbol

lncARSR

Approved Name

lncARSR: lncRNA regulator of Akt signaling associated with HCC and RCC

Characteristics

lncARSR (lncRNA Activated in RCC with Sunitinib Resistance) is located on chromosome 9 in humans and composed of four exons with a full length of 591 nt determined by RACE. [1]

Function

lncARSR acts as a ceRNA for miR-34 and miR-449 to promote AXL and c-MET expression [1] . lncARSR promotes the self-renewal capacity, tumorigenicity and metastasis of renal T-ICs [2]. lncARSR plays a critical role in renal T-ICs propagation and may serve as a prognostic biomarker and potential therapeutic target [2]. lncARSR physically associates with PTEN mRNA, promotes PTEN mRNA degradation, decreases PTEN expression, and activates PI3K/Akt pathway [3]. Long noncoding RNA lncARSR promotes hepatic lipogenesis via Akt/SREBP-1c pathway and contributes to the pathogenesis of nonalcoholic steatohepatitis [4]. Upregulated lncARSR promotes hepatic cholesterol biosynthesis via modulating Akt/SREBP-2/HMGCR pathways [5]

Regulation

Transfection of constitutively active FOXO1 (FOXO1-A3) or FOXO3a (FOXO3a-A3) significantly downregulated lncARSR levels in sunitinib-resistant cells [1]

Diseases

  • Hepatocellular Carcinoma [3]
  • Renal cancer [1]

Expression

lncARSR is preferentially upregulated in renal T-ICs [2] . lncARSR is upregulated in HCC, associated with large tumor size and advanced BCLC stage [3]. Overexpression of lncARSR enhance while knockdown of lncARSR ameliorated hepatic lipid accumulation in vivo and in vitro [4].

Labs working on this lncRNA

  • Department of Urology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China
  • Intensive Care Unit, The Affiliated Hospital of Weifang Medical University, Weifang, Shandong, 261031, China
  • Department of Medical Equipment, Weifang People's Hospital, Weifang, Shandong, 261000, China

References

  1. ↑ 1.0 1.1 1.2 1.3 Qu L, Ding J, Chen C, Wu ZJ, Liu B, Gao Y et al. Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA[J]. Cancer Cell. 2016, 29(5):653-668.
  2. ↑ 2.0 2.1 2.2 Qu L, Wu ZJ, Li YM, Xu ZP, Liu B, Liu F et al. A feed-forward loop between lncARSR and YAP activity promotes expansion of renal tumour-initiating cells[J]. Nature communications. 2016
  3. ↑ 3.0 3.1 3.2 Li YL, Ye Y, Feng BM & Qi Y. Long Noncoding RNA lncARSR Promotes Doxorubicin Resistance in Hepatocellular Carcinoma via Modulating PTEN-PI3K/Akt Pathway[J]. J Cell Biochem. 2017, 118(12):4498-4507.
  4. ↑ 4.0 4.1 Cite error: Invalid <ref> tag; no text was provided for refs named ref4
  5. ↑ Cite error: Invalid <ref> tag; no text was provided for refs named ref5

Sequence

NA

Retrieved from "https://ngdc.cncb.ac.cn/lncrnawiki1/index.php?title=LncARSR&oldid=1275654"